Table 1. Baseline and intervening time point demographic and clinical characteristics of (A) 585 Ethiopian participants and (B) 577 Tanzanian participants included in the analysis of progression of conjunctival scarring.

Characteristic	Progressors		Non-Progressors		P-value
A) ETHIOPIA	N = 135		N = 450
Gender (female)	93	(68.9%)	280	(62.2%)	0.16
Age at baseline, mean (SD)	49.4	(13.4)	50.6	(14.5)	0.42
BMI at baseline, mean (SD)	20.1	(2.4)	20.0	(2.3)	0.73
Scarring severity at baseline					<0.0001
1a	0	-	1	(0.2%)
1b	6	(4.4%)	4	(0.9%)
1c	20	(14.8%)	21	(4.7%)
2	107	(79.3%)	342	(76.0%)
3	2	(1.5%)	82	(18.2%)
Clinically inflamed (P2/P3)
Baseline	71 / 135	(52.6%)	136 / 450	(30.2%)	<0.0001
6-months	26 / 95	(27.4%)	50 / 341	(14.7%)	0.0039
12-months	58 / 130	(44.6%)	84 / 430	(19.4%)	<0.0001
18-months	29 / 131	(22.1%)	60 / 436	(13.8%)	0.021
Clinically inflamed, 1+ episode	97	(71.9%)	192	(42.7%)	<0.0001
Proportion of examinations with inflammation (%)					<0.0001
0%	38	(28.1%)	258	(57.3%)
25%	28	(20.7%)	77	(17.1%)
33%	11	(8.1%)	25	(5.6%)
50%	19	(14.1%)	32	(7.1%)
66%	9	(6.7%)	16	(3.6%)
75%	11	(8.1%)	18	(4.0%)
100%	19	(14.1%)	24	(5.3%)
B) TANZANIA	N = 173		N = 404
Gender (female)	115	(66.5%)	247	(61.1%)	0.23
Age at baseline, mean (SD)	50.9	(17.7)	43.8	(16.9)	<0.0001
BMI at baseline, mean (SD)	21.6	(3.1)	21.8	(2.9)	0.47
Scarring severity at baseline					<0.0001
1a	45	(26.0%)	170	(42.1%)
1b	63	(36.4%)	170	(42.1%)
1c	45	(26.0%)	47	(11.6%)
2	14	(8.1%)	12	(3.0%)
3	6	(3.5%)	5	(1.2%)
Clinically inflamed (P2/P3)
Baseline	46 / 173	(26.6%)	55 / 404	(13.6%)	0.0002
6-months	21 / 152	(13.8%)	15 / 357	(14.7%)	0.0001
12-months	13 / 143	(9.1%)	16 / 335	(4.8%)	0.070
18-months	6 / 135	(4.4%)	3 / 325	(1.0%)	0.013
Clinically inflamed, 1+ episode	53 / 173	(30.6%)	69 / 404	(17.1%)	0.0003
Proportion of examinations with inflammation (%)					0.0011
0%	120	(69.4%)	335	(82.9%)
25%	19	(11.0%)	37	(9.2%)
33%	8	(4.6%)	13	(3.2%)
50%	8	(4.6%)	9	(2.2%)
66%	3	(1.7%)	2	(0.5%)
75%	5	(2.9%)	2	(0.5%)
100%	10	(5.8%)	6	(1.5%)